Stroehmann Diane 4
4 · Sienna Biopharmaceuticals, Inc. · Filed Jan 3, 2019
Insider Transaction Report
Form 4
Stroehmann Diane
See Remarks
Transactions
- Award
Stock Options (Right to buy)
2019-01-01+22,500→ 22,500 totalExercise: $2.32Exp: 2029-01-01→ Common Stock (22,500 underlying) - Award
Stock Options (Right to buy)
2019-01-01+22,500→ 45,000 totalExercise: $2.32Exp: 2029-01-01→ Common Stock (22,500 underlying) - Award
Stock Options (Right to buy)
2019-01-01+14,632→ 14,632 totalExercise: $2.32From: 2019-01-01Exp: 2029-01-01→ Common Stock (14,632 underlying) - Award
Common Stock
2019-01-01+45,000→ 172,640 total
Footnotes (4)
- [F1]Award of restricted stock units ("RSUs") granted under the Issuer's 2017 Incentive Award Plan. Each RSU entitles the Reporting Person to receive one share of Issuer common stock upon vesting. The award vests as to twenty-five percent (25%) of the total number of RSUs on July 1, 2019, twenty-five percent (25%) of the total number of RSUs on January 1, 2020, and the remaining fifty percent (50%) of the total number of RSUs on the second anniversary, in each case, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date.
- [F2]Includes a total of 2,916 shares of the Issuer's common stock acquired pursuant to the Issuer's Employee Stock Purchase Plan.
- [F3]Twenty percent (20%) of the shares subject to the option vest and become exercisable upon satisfaction of one performance-based milestone, forty percent (40%) of the shares vest and become exercisable upon satisfaction of a second performance-based milestone, and the remaining forty percent (40%) of the shares vest and become exercisable upon satisfaction of a third performance-based milestone, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- [F4]Twenty-five percent (25%) of the shares subject to the option vest and become exercisable on July 1,2019, twenty-five percent (25%) of the shares vest and become exercisable on January 1, 2020, and the remaining shares vest and become exercisable in 12 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.